Janssen’s teclistamab gets CMA from European Commission
Teclistamab is the first bispecific antibody worldwide to be approved for patients with relapsed and refractory multiple myeloma - News - PharmaTimes
by Emily Kimber
https://www.pharmatimes.com/news/janssens_teclistamab_gets_cma_from_european_commission_1453944